Lipid Lowering with PCSK9 Inhibition: Long-Term Efficacy, Long-Standing Barriers - Pharmaceutical Executive

Lipid Lowering with PCSK9 Inhibition: Long-Term Efficacy, Long-Standing Barriers  Pharmaceutical ExecutiveQuick Takes: CORALreef | ACC.26  JACC JournalsEnlicitide Superior to Oral Non-Statin Therapies for LDL-C Lowering, With Alberico Catapano, PhD  HCPLiveNovel Cholesterol Drug Outperforms Existing Treatments  European Medical JournalCORALreef AddOn: Enlicitide Outperforms Standard Hypercholesterolemia Drugs, With Ann Marie Navar, MD, PhD  HCPLive